DEA Adds Four New Synthetic Opioids to Schedule I
Published Date: 7/1/2026
Proposed Rule
Summary
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Temporary Schedule I listing for four opioids
The DEA intends to place four synthetic opioids (5,6-dichloro brorphine; 5,6-dichloro desmethylchlorphine; N-propionitrile chlorphine; and spirochlorphine) into Schedule I. When the temporary scheduling order is published (on or after July 31, 2026) these substances will be subject to the regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I drugs, and that temporary control will last two years (with a possible one-year extension).
Possession, manufacture, and trade subject to sanctions
Once the DEA publishes the temporary scheduling order (on or after July 31, 2026), possessing, manufacturing, distributing, importing, or exporting these four named substances will be governed by the Schedule I controls and associated administrative, civil, and criminal sanctions. The temporary scheduling remains in effect for two years from the publication date, with a possible one-year extension.
Research and lab work now tightly restricted
If you engage in research, instructional activities, or chemical analysis involving these four substances, those activities will be subject to Schedule I regulatory controls and the associated administrative, civil, and criminal sanctions once the temporary order is published (on or after July 31, 2026). The temporary controls last for two years from publication, with a possible one-year extension while the government completes the regular scheduling process.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-13302, Integrated Low-Level Radioactive Waste Disposal
The Nuclear Regulatory Commission is updating rules for disposing of low-level radioactive waste, making it safer and more flexible. This affects waste disposal sites, which will now follow a smarter, risk-based system tailored to their specific conditions. Comments on these changes are open until August 17, 2026, giving everyone a chance to weigh in before new rules roll out.
Next: 2026-13365, Airworthiness Directives; MD Helicopters, LLC Helicopters
The FAA wants owners of certain MD Helicopters models to check their main transmission drive shaft couplings for cracks. If cracks are found, the couplings must be replaced to keep flights safe. Comments on this plan are open until August 17, 2026, and the inspection is a one-time fix that helps avoid costly repairs or accidents later.